Compare Core Scientific Inc (CORZ) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs CVS Health Corp — how do they compare? Core Scientific Inc trades at $15.61 (market cap $5.12B), while CVS Health Corp trades at $86.25 (market cap $112.29B). The key difference: CVS Health Corp is far larger — about 21.9× Core Scientific Inc's market cap, and CVS Health Corp pays a 3.03% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and CVS Health Corp for 83 Days on average.
| CORZ | CVS | |
|---|---|---|
Market Cap | $5.12B | $112.29B |
Volume | 9,296,664 | 7,763,676 |
Sector | Technology | Health |
52-Week High | $29.16 | $110.60 |
52-Week Low | $13.57 | $70.08 |
Typical Hold Time | 20 Days | 83 Days |
Enterprise Value | $7.65B | $174.64B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.94, down 4.44% today amid bearish technical signals. The stock shows weak fundamentals with a -324.9% net income margin and negative earnings misses in recent quarters. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.46 consensus price target. Recent executive appointments and AI data center expansion plans provide growth catalysts despite current profitability challenges.
The outlook balances strong analyst conviction against fundamental weakness. While the AI infrastructure pivot offers long-term potential, investors face significant execution risks and negative cash flow. The stock trades near support levels with technical indicators suggesting caution, requiring careful monitoring of revenue growth and margin improvement for sustained recovery.
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
